Constipation - Pipeline Review, H2 2019

Global Markets Direct’s, ‘Constipation - Pipeline Review, H2 2019’, provides an overview of the Constipation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Constipation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Constipation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Constipation

- The report reviews pipeline therapeutics for Constipation by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Constipation therapeutics and enlists all their major and minor projects

- The report assesses Constipation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Constipation

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Constipation

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Constipation pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Ardelyx Inc

Bausch Health Companies Inc

Braintree Laboratories Inc

Dong-A ST Co Ltd

Enterin Inc

Inhibikase Therapeutics Inc

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical ...

Allergan Plc

Ardelyx Inc

Bausch Health Companies Inc

Braintree Laboratories Inc

Dong-A ST Co Ltd

Enterin Inc

Inhibikase Therapeutics Inc

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Mallinckrodt Plc

NGM Biopharmaceuticals Inc

RaQualia Pharma Inc

Renexxion LLC

Sanwa Kagaku Kenkyusho Co Ltd

Synthetic Biologics Inc

Yuhan Corp

Zensun (Shanghai) Sci & Tech Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Constipation – Overview

Constipation – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Constipation – Overview

Constipation – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Constipation – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Constipation – Companies Involved in Therapeutics Development

Allergan Plc

Ardelyx Inc

Bausch Health Companies Inc

Braintree Laboratories Inc

Dong-A ST Co Ltd

Enterin Inc

Inhibikase Therapeutics Inc

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Mallinckrodt Plc

NGM Biopharmaceuticals Inc

RaQualia Pharma Inc

Renexxion LLC

Sanwa Kagaku Kenkyusho Co Ltd

Synthetic Biologics Inc

Yuhan Corp

Zensun (Shanghai) Sci & Tech Co Ltd

Constipation – Drug Profiles

5-BIOP – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Irritable Bowel Syndrome with Constipation – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLI-400 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLI-801 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-6886 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IkT-148009 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lactulose 1 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lovastatin MR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lubiprostone – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mizagliflozin – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plecanatide – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000010 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenapanor – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-12852 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZS-06 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Constipation – Dormant Projects

Constipation – Discontinued Products

Constipation – Product Development Milestones

Featured News & Press Releases

Jul 22, 2019: Ironwood Pharmaceuticals Allergan provides update on its ANDA Lawsuit

Jun 26, 2019: Knight announces filing of New Drug Submission for Ibsrela in Canada

Jun 20, 2019: Ironwood and Allergan’s LINZESS trial meets primary endpoint

May 14, 2019: Salix Pharmaceuticals presents data on TRULANCE at Digestive Disease Week

May 09, 2019: Ironwood Pharmaceuticals to highlight linaclotide data at Digestive Disease Week 2019

Jan 18, 2019: Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation

Jan 04, 2019: Ironwood and Allergan settle Linzess patent litigation with Mylan

Jan 03, 2019: Synthetic Biologics announces first two patients enrolled in phase 2b investigator-sponsored

Dec 17, 2018: Cipher Pharmaceuticals announces PLECANATIDE accepted for review by Health Canada

Nov 13, 2018: Ardelyx announces FDA acceptance of the filing of its New Drug Application for Tenapanor for the treatment of patients with IBS-C

Oct 25, 2018: Synergy Pharmaceuticals provides business update

Oct 08, 2018: Synergy pharmaceuticals presents new analyses supporting the use of TRULANCE (Plecanatide) in two patient populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting

Oct 08, 2018: Ironwood Pharmaceuticals presenting Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting

Oct 08, 2018: Ardelyx showcases new data from T3MPO-3 long-term safety trial of Tenapanor for IBS-C in presidential poster at ACG 2018 Annual Meeting

Oct 01, 2018: Synergy Pharmaceuticals to present new analyses of TRULANCE (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Constipation, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under ...

List of Tables

Number of Products under Development for Constipation, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Constipation – Pipeline by Allergan Plc, H2 2019

Constipation – Pipeline by Ardelyx Inc, H2 2019

Constipation – Pipeline by Bausch Health Companies Inc, H2 2019

Constipation – Pipeline by Braintree Laboratories Inc, H2 2019

Constipation – Pipeline by Dong-A ST Co Ltd, H2 2019

Constipation – Pipeline by Enterin Inc, H2 2019

Constipation – Pipeline by Inhibikase Therapeutics Inc, H2 2019

Constipation – Pipeline by Ironwood Pharmaceuticals Inc, H2 2019

Constipation – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019

Constipation – Pipeline by Mallinckrodt Plc, H2 2019

Constipation – Pipeline by NGM Biopharmaceuticals Inc, H2 2019

Constipation – Pipeline by RaQualia Pharma Inc, H2 2019

Constipation – Pipeline by Renexxion LLC, H2 2019

Constipation – Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019

Constipation – Pipeline by Synthetic Biologics Inc, H2 2019

Constipation – Pipeline by Yuhan Corp, H2 2019

Constipation – Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2019

Constipation – Dormant Projects, H2 2019

Constipation – Dormant Projects, H2 2019 (Contd..1), H2 2019

Constipation – Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development for Constipation, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by ...

List of Figures

Number of Products under Development for Constipation, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports